

*REMARKS*

*Submission of Sequence Listing*

Applicants hereby submit a corrected nucleotide/amino acid sequence listing.

Applicants gratefully acknowledge the error report that accompanied the Notice, and have corrected the errors identified therein in compliance with the requirements of 37 C.F.R. § 1.821-1.825. The corrected sequence listing is submitted herewith in both paper copy and computer-readable form. The undersigned hereby verifies that the content of the paper copy and the computer-readable form are identical. The undersigned verifies that the corrected sequence listing does not include any new matter.

*Amendments to the Specification*

The specification is amended to correct typographical errors. Specifically, the paragraph bridging lines 22-28 of page 30 is amended to properly refer to the indicated sequences using the correct SEQ ID NOs. This amendment adds no new matter to the application. A marked-up copy of the paragraph, indicating the changes made thereto, is attached.

*Conclusion*

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted

M. Daniel Hefner, Reg. No. 41,826  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: April 25, 2003



**PATENT**  
Attorney Docket No. 219604  
Client Reference No. KAUS430501

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

KASID et al.

Group Art Unit: unassigned

Application No. 10/075,994

Examiner: unassigned

Filing Date: February 15, 2002

For: CHEMOSENSITIZING WITH LIPOSOMES  
CONTAINING OLIGONUCLEOTIDES

**INDICATION OF AMENDMENTS MADE TO SPECIFICATION**

Note, deleted text appears in brackets, added text appears in underlining and with highlighting because certain portions of the text already are underlined.

A 20-mer phosphorothioate antisense ODN (ISIS 5132/5132: 5' TCC-CGC-CTG-TGA-CAT-GCA-TT-3' (SEQ ID NO:5[4]) corresponding to the 3' untranslated region (3'UTR) of human *c-raf-1* mRNA and a seven base mismatched phosphorothioate antisense ODN (ISIS 10353/10353; 5'-TCC-CGC-GCA-CTT-GAT-GCA-TT-3') (SEQ ID NO:6[5]) were designed and synthesized as described previously (Monia et al., 1996a,b). A 20-mer phosphorothioate sense ODN (5'-ATT-GCA-TGT-CAC-AGG-CGG-GA-3') (SEQ ID NO:7[6]) was synthesized at Loftstrand Labs Limited (Gaithersburg, MD) as described previously (Soldatenkov et al., 1997).